

Health and Safety Executive

Consultation on proposed regulations to implement Council Directive 2010/32/EU on preventing sharps injuries in the hospital and healthcare sector.

Reply Form

Completing this Questionnaire

You can move between questions by pressing the 'Tab' / 'Shift-Tab' or 'Page Up' / 'Page Down' keys or by clicking on the grey boxes with a mouse. Please type your replies within the rectangular grey boxes, or click on the square grey boxes to select an answer (e.g. 'Yes' or 'No').

Respondent's details:

| Name: | Ruth Wakeman |
|-----------------|------------------------------|
| Email: | ruth.wakeman@rpharms.com |
| Town / City: | London |
| Telephone: | 020 7572 2615 |
| Job Title: | Head of Professional Support |
| Postcode: | SE1 7JN |
| Street address: | 1 Lambeth High Street |
| Organisation: | Royal Pharmaceutical Society |
| Fax: | |



| Size of organisation: | | | |
|-------------------------------|---|------------------------------|--|
| Choose one option: | | | |
| Not applicable | Χ | 1 to 9 employees | |
| 10 to 49 employees | | 50 to 249 employees | |
| 250 to 1000 employees | | 1000+ employees | |
| Self-employed | | | |
| * | | | |
| Type of organisation: | | | |
| Choose one option: | | | |
| Academic | | Charity | |
| Consultancy | | Industry | |
| Local government | | Member of the public | |
| National government | | Non-departmental public body | |
| Non-governmental organisation | | Pressure group | |
| Trade association | | Trade union | |
| | | - | |

Professional body

Other - please specify:



Is your response being made in your capacity as: Choose one option: An employer An employee Health and safety professional Trade union official Self-employed person Training provider Other - please specify: Professional body for pharmacy Confidentiality Please indicate below if you do not wish details of your comments to be available to the public. (NB if you do not put a cross in the box they will be made available to the public. This takes precedence over any automatic notes on e-mails that indicate that the contents are confidential.) Q1. Is the use of 'medical sharps' in the regulations (see page 5) consistent with how it is commonly used by employers and workers in the healthcare sector? Yes No $X \square$ If you have answered 'No', please provide details to support your answer.



We welcome the Directive as an important contribution to reducing the risk of sharps injury and consequential infection risks to healthcare staff in patient care areas. However it is also important to consider the use of sharps in a pharmacy context, this directive has implications for them and we urge that the views of pharmacy teams working in these areas are considered as part of this consultation. Sharps are used in pharmacy aseptic compounding services to prepare doses of injectable medicines for patient use which would otherwise be made in clinical areas with much increased risk of calculation and measurement errors as well as of microbial contamination. During complex manipulations needles may be removed and replaced more than once and resheathing is integral to practice. The critical difference between this and use of sharps in clinical areas is that in the pharmacy context, there is no risk that any sharps will be contaminated with body fluids or pathogens.

| Q2. In addition to the examples provided (see page 10 and paragraphs 17-22), are there other common circumstances under which people carry out healthcare activities using medical sharps where the application of the proposed regulations could usefully be clarified in guidance? | | | | | |
|--|--|--|--|--|--|
| Yes No X | | | | | |
| If you have answered 'Yes', please provide details to support your answer. | | | | | |
| | | | | | |
| | | | | | |
| Q3. Is it clear what actions employers and employees will need to take under the proposed regulations (see paragraphs 27-29)? | | | | | |
| Yes No X | | | | | |



Please provide comments to support your answer.

| There may be implications for pharmacy for sourcing and procuring safer devices and providing training in their use. |
|--|
| Expert pharmacy groups have advised us that a total ban on re-sheathing would require re-design of aseptic compounding processes. It is as yet unclear what "safer" devices are available to address this, how they could be used and what the cost and other implications would be. |
| |
| Q4a. Do you agree that HSE's guidance on the new Regulations should be built into its existing relevant guidance (see page 15)? |
| |
| |
| Yes X No \ |
| |
| Q4b. In addition to the organisations that produced the guidance listed at paragraphs 31 and 32 are there other organisations that HSE should seek to work with to ensure that relevant non-HSE guidance aligns with the requirements of the new regulations? |
| |
| |
| |
| |
| |
| |



| Q5. Does the proposed implementation date have any unintended consequences for the UK healthcare sector? |
|--|
| |
| Yes No X |
| Please provide comments to support your answer. |
| |
| |
| |
| Q6. To assist us with the impact assessment please answer the following: |
| a) Numbers of employers in the healthcare sector |
| IA1. Please provide any information you have which will help us to fill in the gaps in Table 1 with appropriate references to the source of information. |
| Hospitals |
| |
| |
| |
| |



| GPs |
|-------------------------|
| |
| |
| |
| |
| |
| |
| |
| |
| Dental Surgeries |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| Ambulance Services |
| |
| |
| |
| |
| |
| |
| |
| |
| Care Homes and Hospices |



| b) Review of Risk Assessments |
|--|
| IA2. Do you agree with the following assumptions made by HSE in the impact assessment: |
| All risk assessments relevant to sharps injuries will have to reviewed. |
| |
| |
| Yes No 🗆 |
| |
| Please provide comments to support your answer. |
| |
| |
| |
| |
| |
| |
| |

It will take each hospital and ambulance trust between 2 and 3 hours to review the relevant risk assessments.



| Yes No |
|---|
| Please provide comments to support your answer. |
| |
| |
| It will take GPs, dental practices and care homes between 0.5 hours and 1 hour to review the relevant risk assessments. |
| Yes No |
| Please provide comments to support your answer. |
| |
| |
| IA4. Can you estimate how many risk assessments your organisation may need to amend as a |



| result of the proposed regulations? |
|--|
| |
| |
| |
| IA5. How long will it take your organisation to make amendments to a risk assessment? Please provide your answer in hours/minutes. |
| |
| |
| |
| |
| c) Safer sharps |
| IA6. Does your organisation use any 'safer sharps' in its activities now? |
| |
| Yes No |
| IA7. Will your organisation use an increased number of 'safer sharps' as a result of the |
| proposed regulations? |



| Yes | | No | | | | |
|--------------|-----------------|------------------|---------------|-------------|---|----------|
| organisatio | - | he proposed re | egulations, v | | the use of safer sha 0% is that all possible | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| d) Familiari | sation | | | | | |
| assessmen | | sation cost (in | _ | _ | made by HSE in the in it will take to r3ead a | _ |
| a) For each | hospital and am | ıbulance servi | ce between 5 | ភ and 10 រុ | people will have to sp | end time |
| familiarisin | g themselves wi | th the propose | d regulation | s. | | |
| | | | | | | |
| | | | | | | |
| Agree | | Disagree | | | Not within my knowledge | |
| If you have | answered 'Disaເ | gree', please ca | an you sugg | est an alt | ernative figure: | |
| | | | | | | |



| | | | | | rson will spend time |) |
|--------------|---------------|---------------------|--------------|----------|----------------------|----------|
| familiarisin | g themselves | with the proposed | regulations. | | | |
| | | | | | | |
| | | | | | | |
| Agree | | Disagree | | | Not within my | |
| | | | | _ | knowledge | |
| | | | | | | |
| If you have | answered 'Dis | sagree', please car | n you sugges | t an alt | ernative figure: | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | d between 1 and 3 | hours readin | g and ι | understanding the p | proposed |
| regulations | | | | | | |
| | | | | | | |
| | | | | | | |





| Agree | | Disagree | | | Not within my knowledge | |
|--|----------------|---------------------|--|--|----------------------------|---------------|
| If you have answered 'Disagree', please can you suggest an alternative figure: | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | e provide info | rmation about the o | | | g from other require | ements in the |
| a) Placing of secure containers and instructions for safe disposal of medical sharps close to the work area | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |





| Published cost data, please provide the appropriate reference. |
|--|
| Published cost data, please provide the appropriate reference. |
| Published cost data, please provide the appropriate reference. |
| Published cost data, please provide the appropriate reference. |
| Published cost data, please provide the appropriate reference. |
| Published cost data, please provide the appropriate reference. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| Summary of cost data already collated by your organisation – please set out below or provide a |
| summary of what it covers: |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |



| Please provide contact details for obtaining a copy of this data: | | |
|---|--|--|
| | | |
| | | |
| | | |
| | | |
| | | |
| b) Not recapping needles where there is a risk of injury | | |
| Published cost data, please provide the appropriate reference. | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Summary of cost data already collated by your organisation – please set out below or provide a summary of what it covers: | | |
| | | |
| | | |
| | | |
| | | |
| | | |



| Please provide contact details for obtaining a copy of this data: |
|---|
| |
| |
| |
| c) Procedures to be reviewed regularly |
| Published cost data, please provide the appropriate reference. |
| |
| |
| |
| |
| Summary of cost data already collated by your organisation – please set out below or provide a summary of what it covers: |





| Please provide contact details for obtaining a copy of this data: |
|---|
| ricase provide contact details for obtaining a copy of this data. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| d) Information and training |
| |
| Published cost data, please provide the appropriate reference. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| · · · · · · · · · · · · · · · · · · · |





| Summary of cost data already collated by your organisation – please set out below or provide a summary of what it covers: |
|---|
| |
| Please provide contact details for obtaining a copy of this data: |
| |
| |
| |
| f) Follow up of a sharps injury Published cost data, please provide the appropriate reference. |
| |
| |



| Summary of cost data already collated by your organisation – please set out below or provide a summary of what it covers: | | |
|---|--|--|
| | | |
| | | |
| | | |
| | | |
| Please provide contact details for obtaining a copy of this data: | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| IA11. Benefits | | |
| If you are able to identify any anticipated benefits to you (eg reduced costs of injuries) from implementation of the changes required by the proposed Regulations, please provide a description. | | |
| | | |
| | | |
| | | |



| Is there anything you particularly like or dislike about this consultation? Please provide comments. | · |
|--|-------|
| | |
| Do you have any other comments on the proposals that have not been covered by this questionnaire? | |
| We have concerns regarding the implications for safe practice in pharmacy asentic preparation | ∩ |

services and we urge that the views of pharmacy teams working in these areas are considered as part of this consultation. We are also concerned that there is no acknowledgement of the role of pharmacy

in providing safe, ready to use injectable medicines.

Please send your response by 8 November 2012 to:

Martin Dilworth
Health and Safety Executive,
5S2 Redgrave Court,
Merton Road
Bootle L20 7HS

Tel: 0151 951 4335 Fax: 0151 951 4575

E mail: sharpsconsultation@hse.gsi.gov.uk

Thank you for taking the time to complete this questionnaire



